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Abstract
Background: The use of abciximab (c7E3 Fab) or eptifibatide improves clinical outcomes in
diabetics undergoing percutaneous coronary intervention. These β3 integrin inhibitors antagonize
fibrinogen binding to αIIbβ3 integrins on platelets and ligand binding to αvβ3 integrins on vascular
cells. αvβ3 integrins influence responses to insulin in various cell types but effects in human aortic
smooth muscle cells (HASMC) are unknown.
Results and discussion: Insulin elicited a dose-dependent proliferative response in HASMC.
Pretreatment with m7E3 (an anti-β3 integrin monoclonal antibody from which abciximab is
derived), c7E3 or LM609 inhibited proliferative responses to insulin by 81%, 59% and 28%,
respectively. Eptifibatide or cyclic RGD peptides completely abolished insulin-induced proliferation
whereas tirofiban, which binds αIIbβ3 but not αvβ3, had no effect. Insulin-induced increases in c-Jun
NH2-terminal kinase-1 (JNK1) activity were partially inhibited by m7E3 and eptifibatide whereas
antagonism of αvβ3 integrins had no effect on insulin-induced increases in extracellular signal-
regulated kinase (ERK) activity. Insulin stimulated a rapid increase in the number of vinculin-
containing focal adhesions per cell and treatment with m7E3, c7E3 or eptifibatide inhibited insulin-
induced increases in focal adhesions by 100%, 74% and 73%, respectively.
Conclusion: These results demonstrate that αvβ3 antagonists inhibit signaling, focal adhesion
formation and proliferation of insulin-treated HASMC.
Background
Individuals with insulin resistance states and elevated lev-
els of circulating insulin, the prototype of which is type II
diabetes, are more prone to develop vascular disease and
less likely to benefit from available treatments compared
to non-diabetic individuals[1]. Abciximab and eptifi-
batide, two widely used integrin inhibitors, improve mor-
tality in diabetics undergoing percutaneous coronary
intervention (PCI). In a pooled analysis of three large clin-
ical trials, abciximab was associated with a 44% reduction
in one year mortality in diabetics (4.5% in patients receiv-
ing placebo and 2.5% in patients receiving abciximab)[2].
Similarly, eptifibatide was associated with a reduction in
one year mortality in diabetics (3.5% in patients receiving
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Enhanced Suppression of the platelet IIb/IIIa Receptor
with Integrilin Therapy (ESPRIT) trial[3].
Abciximab and eptifibatide, in addition to inhibiting platelet
aggregation via antagonism of fibrinogen binding to αIIbβ3
integrins, also antagonize ligand binding to αvβ3 integrins on
vascular cells[4,5]. Recent studies in cultured cells have
revealed considerable cross-talk between αvβ3 integrins and
insulin receptor-mediated signals. Vuori and Ruoslahti[6]
found that αvβ3 integrins associate with insulin-receptor sub-
strate-1 (IRS-1), a docking protein that phosphorylates on
tyrosine following insulin-receptor activation and binds SH2
domain-containing proteins that propagate the insulin sig-
nal. Moreover, αvβ3 integrins associated with tyrosine phos-
phorylated insulin receptors and other, as yet unidentified,
tyrosine phosphorylated proteins in insulin-treated fibrob-
lasts[7]. These associations were specific for αvβ3 integrins
and proliferative responses to insulin were enhanced by
extracellular matrices that ligated αvβ3 integrins. More
recently, Lopez-Alemany et al. reported that plasminogen
activator inhibitor-1 (PAI1) competes with αvβ3 integrins for
binding to vitronectin and by this mechanism blocks insu-
lin-induced migration in NIH3T3 cells and human umbili-
cal vein endothelial cells[8].
Given the important role of smooth muscle cell (SMC)
proliferation in atherosclerosis progression and in revas-
cularization failures, the present studies were performed
to explore the hypothesis that abciximab and eptifibatide
inhibit proliferative responses of human aortic SMC
(HASMC) to insulin via antagonizing αvβ3 integrins.
Methods
Cell culture, proliferation assays and flow cytometric 
analysis
HASMC were obtained from Clonetics (San Diego, CA)
and maintained in culture as previously described[4].
SMC between passages 4 and 15 were used in these stud-
ies. The cells were grown in media that was a 1:1 mixture
of regular DMEM and smooth muscle proliferation
medium with a glucose concentration of 15.27 mM. Cell
proliferation, flow activated cell sorting (FACS) analysis,
apoptosis assays, focal adhesion assays and cell adhesion
assays were performed as previously described[4,9].
Reagents
m7E3 and c7E3 Fab were provided by Centocor (Malvern,
Pa). Eptifibatide was provided by Cor Therapeutics (South
San Francisco, CA). Insulin and peptide integrin inhibi-
tors were purchased from Sigma (St. Louis, MO).
Transfection and selection of stable β3 integrin expressing 
HEK cells
pcDNA-1neo constructs encoding full-length β3 subunits
were a gift of D. Cheresh (Scripps Research Institute, La
Jolla, CA) and have been previously described[10]. β3
integrin-deficient HEK 293 cells (ATCC; Manassas, VA)
were transfected using the FuGENE Transfection Reagent
(Boehringer Mannheim) and stable cell lines established
as previously described[5].
JNK1 kinase activity assay
HASMC were grown to subconfluence and then growth
arrested for 48 hours in DMEM containing 0.1% FBS.
Cells were pretreated with m7E3, c7E3 or eptifibatide for
1 hour, and then stimulated for 10 min at 37°C with 1 uM
Insulin (Sigma). Cells were washed twice with ice-cold
PBS containing 0.5 mM vanadate and then lysed with ice-
cold cell lysis buffer plus protease inhibitor cocktail
(Roche Diagnostics GmbH) on ice for 10 minutes. JNK1
kinase activity was measured using a GST-c-JUN pull-
down assay as previously described[9].
Statistical analysis
Results are expressed as mean ± standard deviation unless
otherwise stated. One way analysis of variance followed
by the Dunnett's multiple range test was used to analyze
data. A p value of less than or equal to 0.05 was consid-
ered statistically significant. Triplicate wells were analyzed
for each experiment and each experiment was performed
independently a minimum of three times.
Results
HASMC express αvβ3 integrins
Flow cytometry was performed utilizing LM609, a mon-
oclonal antibody that binds αvβ3 integrins with high
specificity[11], m7E3, a monoclonal anti-β3 integrin
antibody from which abciximab is derived, and 10E5, a
monoclonal antibody that binds αIIbβ3 but not αvβ3.
Results demonstrated that HASMC express αvβ3 and
that β3 subunits form heterodimers primarily, if not
solely, with αv subunits in HASMC (figures 1A and 1B;
binding to HASMC in arbitrary binding units: no anti-
body 1.0 ± 0.2, 10E5 1.4 ± 0.2, m7E3 3.1 ± 0.3 and
LM609 3.2 ± 0.5; p < 0.05 for m7E3 vs. 10E5 and
LM609 vs. 10E5).
Apoptosis, as determined by Annexin V binding to the cell
surface, was present in less than 10% of HASMC main-
tained in quiescent media for 120 hours (figure 1C) and
did not increase with insulin treatment. Treatment with
various integrin inhibitors for 48 hours after HASMC had
been maintained in quiescent media for 72 hours did not
increase the number of apoptotic SMC, either with or
without insulin. At the concentrations used in these stud-
ies, neither m7E3, c7E3 nor eptifibatide had any effect on
cell adhesion (figure 1D). These results are consistent with
prior studies showing that attachment of HASMC to non-
coated tissue culture plates is primarily mediated by vari-
ous β1-integrins[12].Page 2 of 11
(page number not for citation purposes)
Cardiovascular Diabetology 2008, 7:36 http://www.cardiab.com/content/7/1/36
Page 3 of 11
(page number not for citation purposes)
Expression of αvβ3 integrins by HASMC and effect of αvβ3 antagonists on cell adhesion and apoptosisFigure 1
Expression of αvβ3 integrins by HASMC and effect of αvβ3 antagonists on cell adhesion and apoptosis. Results of a 
representative FACS experiment (A) and data from 5 independent experiments (B) are shown (* = p < 0.05 vs no antibody or 
vs 10E5). HASMC growth-arrested for 72 hours were treated with insulin (1 μmol/L) or vehicle ± integrin inhibitors. 48 hours 
later (120 hours after the addition of quiescent media), Annexin V staining was determined (C). The groups are as follows: 1 – 
no inhibitor, 2 – 10E5, 3 – m7E3, 4 – c7E3, 5 – LM609, 6 – eptifibatide, 7 – tirofiban, 8 – cRGD, 9 – RGD, 10 – RGE and 11 – 
RAD. HASMC in suspension were incubated with eptifibatide, RGE peptides, m7E3 or 10E5 and then added to non-coated tis-
sue culture plates. Cell adhesion was determined as described in Methods (D). Concentrations of inhibitors were as follows: 
m7E3, c7E3, LM609 and 10E5 (30 μg/ml); eptifibatide, GRGDS, GRDGS or GRADSP peptides (10 μmol/L) and tirofiban (30 
μmol/L).
A. B.
D.C.
* *
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HASMC
Insulin elicited a dose-dependent proliferative response of
HASMC that were growth arrested in 0.5% FBS for 72
hours prior to treatment. The proliferative response, as
determined by cell number assays three days after treat-
ment, to insulin at a concentration of 1 μmol/L (107 ±
18% increase in cell number; n = 7; range 25 – 168%) was
similar to that elicited by platelet-derived growth factor-
BB (PDGF-BB) (figure 2A; 85 ± 14%; n = 3; p = ns com-
pared to insulin).
Treatment of HASMC with m7E3 (30 μg/ml) for one hour
prior to the addition of insulin inhibited proliferative
responses by approximately 70% (figure 2B). The inhibi-
tory effects of 60 μg/ml or 100 μg/ml of m7E3 on insulin-
induced proliferation were the same as that observed with
30 μg/ml (p = ns for differences between various concen-
trations).
Pretreatment with LM609 at the same dose also inhibited
proliferative responses to insulin but to a lesser extent.
m7E3 had a more profound inhibitory effect than LM609
even though the affinity of m7E3 for HASMC (KD = 3.8 ±
0.4 nmol/L) is an order of magnitude less than that of
LM609 for HASMC (KD = 0.18 ± 0.01 nmol/L)[5]. Pre-
treatment with 10E5 had no effect.
c7E3 Fab (abciximab) is a chimeric antigen binding frag-
ment derived from m7E3 which was designed to mini-
mize antigenicity when given to humans. It contains the
heavy and light chain variable regions from the murine
antibody attached to the constant regions of human IgG1
and kappa chains, respectively. Pretreatment with c7E3
(30 μg/ml) inhibited 56% of the proliferative response to
insulin. There was no additional inhibitory effect
observed with higher concentrations of c7E3.
Two other β3 integrin antagonists, eptifibatide and
tirofiban, are used in clinical medicine in addition to
abciximab. Pretreatment of HASMC with eptifibatide at a
concentration of 5 μmol/L blocked 83% of insulin-
induced proliferation (figure 2C). At higher concentra-
tions, eptifibatide completely abolished insulin-induced
proliferation. In contrast, tirofiban, a nonpeptide deriva-
tive of tyrosine that does not bind αvβ3 integrins, had no
effect.
Cyclic RGD peptides (GPenGRGDSPCA; cRGD) are spe-
cific αv antagonists that recognize both αvβ3 and αvβ5[13].
cRGD block αvβ3-mediated migration and proliferation of
rat aortic SMC, αvβ5-mediated adhesion of RASMC to vit-
ronectin and neointimal formation following rat carotid
artery balloon injury[9,13,14]. At a concentration of 10
μmol/L, cRGD completely inhibited insulin-induced pro-
liferation (figure 2C). RDG and RAD peptides, used as
controls, blocked 39% and 31% of the proliferative
response to insulin, respectively (p < 0.05 compared to
insulin alone).
Inhibitory effects of m7E3 are mediated by αvβ3 
antagonism
Further confirmation that the inhibitory effects of m7E3
on responses to insulin were mediated via αvβ3 antago-
nism was provided by studies in human embryonic kid-
ney (HEK) cells that express αv subunits but not β3
subunits. These cells were transfected with pcDNA-1neo
constructs[10] encoding β3 integrin subunits and stable
expression of β3 integrins and formation of αvβ3 com-
plexes was confirmed by immunoprecipitation with
LM609 followed by Western analysis[5]. HEK cells that
expressed β3 subunits proliferated at a rate that was 46%
greater than mock-transfected HEK cells when grown in
5% serum on standard tissue culture plates (figure 3A).
Interestingly, β3-HEK cells showed a significant prolifera-
tive response to 0.5% serum in contrast to mock-trans-
fected HEK cells. Insulin was a potent mitogen for both
β3-transfected and mock-transfected HEK cells; in both
cell types proliferative responses to insulin were greater
than to 5% serum. But, whereas m7E3 had no effect on
insulin-induced proliferation in mock-transfected HEK
cells, m7E3 inhibited approximately 60% of insulin-
induced proliferation in β3-transfected HEK cells (figure
3B).
αvβ3 antagonists inhibit insulin-induced JNK, but not 
insulin-induced ERK, activity
Exposure to insulin results in the stimulation of multiple
signaling pathways[15,16] but mitogen activated protein
kinases (MAPK) are generally thought to regulate biologi-
cal actions related to growth and proliferation[17]. Since
integrins mediate activation of extracellular signal-regu-
lated kinase (ERK)[18] and c-Jun NH2-terminal kinase-1
(JNK1; also known as stress-activated protein kinase-1)[9]
we next sought to determine if αvβ3 antagonists influ-
enced insulin-induced ERK or JNK1 activity. Treatment
with insulin elicited a mild increase in ERK 1/2 phospho-
rylation but pretreatment with eptifibatide, m7E3 or
c7E3, at concentrations that reduced proliferation, had no
effect on this response (figure 4A). In particular, neither
m7E3 at a concentration that reduced insulin-induced
proliferation by approximately 80%, c7E3 at a concentra-
tion that reduced insulin-induced proliferation by
approximately 55% nor eptifibatide at a concentration
that inhibited insulin-induced proliferation by 83% had
any discernible effect on levels of tyrosine phosphorylated
ERK.
Previous studies have shown JNK1 is phosphorylated in
response to treatment of HASMC with insulin[19]. ToPage 4 of 11
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Effect of αvβ3 antagonists on insulin-induced proliferationFigure 2
Effect of αvβ3 antagonists on insulin-induced proliferation. Growth arrested HASMC were treated with insulin (various 
concentrations), PDGF-BB (1.4 nmol/L) or vehicle and cell number was determined three days later (A). In the experiments 
represented in panels B and C, HASMC were treated with antibodies or peptides as indicated for one hour prior to addition of 
insulin (1 μmol/L). Concentrations of antibodies and peptides were the same as in figure 1 unless indicated. [* = p < 0.05 vs 
control (A); * = p < 0.05 vs 10E5 (B); * = p < 0.05 vs tirofiban (C)]
A
B
C
*
*
*
** * * *
* *
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Effects of m7E3 on proliferative responses of HEK cellsFigure 3
Effects of m7E3 on proliferative responses of HEK cells. β3 integrin-deficient HEK cells were transfected with an empty 
vector or pcDNA-1neo constructs encoding full-length β3 integrin subunits. The cells were grown in serum-containing media 
(0.5% or 5%) or insulin (1 μmol/L) for five days (A). In panel B, insulin (1 μmol/L) was added ± m7E3 or 10E5 (20 μg/ml). Cell 
number assays were performed 5 days later. [* – p < 0.05 vs 0.5% FBS in A and * – p < 0.05 vs insulin or insulin + 10E5 in B].
A
B
*
*
*
*
*
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Effect of c7E3, m7E3 and eptifibatide on insulin-induced ERK and JNK activationFigure 4
Effect of c7E3, m7E3 and eptifibatide on insulin-induced ERK and JNK activation. Growth arrested HASMC were 
treated with m7E3, c7E3 or eptifibatide (indicated concentrations in A, both antibodies were used at 30 μg/ml and eptifibatide 
at 10 μmol/L in B and C) as indicated for one hour. Insulin (1 μmol/L) or vehicle was added and ten minutes later ERK and 
JNK1 activity were determined as described in Methods.
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induced activation of JNK1, we utilized an in vitro immu-
nocomplex kinase assay with GST-c-jun as the substrate.
Others have previously shown using the same experimen-
tal system that α-thrombin stimulation of JNK-1 activity is
associated with subsequent increases in c-jun expression,
AP-1-DNA binding activity and AP-1 transactivation activ-
ity[20]. Pretreatment with m7E3, c7E3 or eptifibatide for
one hour reduced insulin-induced JNK1 activity measured
10 minutes after treatment of HASMC (figures 4B and
4C).
Insulin stimulates the formation of focal adhesions and this 
effect is partially inhibited by αvβ3 antagonists
There is evidence that efficient activation of JNK1 in SMC
occurs at focal adhesions, sites where integrins, cytoskele-
tal proteins and signaling proteins converge[21]. Focal
adhesions form at the ends of F-actin stress fibers and
transmit tension between the contractile apparatus and
extracellular matrix. Previously we found that αvβ3 antag-
onists inhibited JNK1 activation and focal adhesion for-
mation in SMC in response to treatment with α-
thrombin[9]. Treatment with insulin resulted in a 66%
increase in focal adhesions (as determined by vinculin
staining) within 5 minutes (figure 5). In a growth arrested,
quiescent state there were 31 ± 3 focal adhesions per
HASMC and this number increased to 49 ± 2 following
five minute exposure to insulin. Pretreatment with m7E3
completely inhibited insulin-induced increases in focal
adhesions. Insulin-induced increases in focal adhesions
were inhibited by 74% and 73% by pretreatment with
c7E3 or eptifibatide, respectively.
Discussion
Antagonism of αvβ3 integrins markedly inhibits prolifera-
tive responses of HASMC to insulin. This conclusion is
based on our findings that insulin-induced proliferation
was inhibited by anti-β3 integrin monoclonal antibody
(m7E3), chimeric antigen binding fragment of 7E3
(c7E3), anti-αvβ3 monoclonal antibody (LM609), anti-β3
peptides (eptifibatide) and anti-αv peptides (cRGD).
These studies add to the wealth of data that αvβ3 antago-
nists have profound effects on SMC proliferation and
migration, two mechanisms that play central roles in vas-
cular pathology. In various studies, αvβ3 antagonists have
been shown to inhibit proliferative responses of SMC to
insulin, thrombospondin, thrombin, IGF-1, osteopontin,
Del1 and transforming growth factor-β and to inhibit
migratory responses of SMC to insulin-like growth factor-
1 – (IGF-1), PDGF, vitronectin, thrombospondin and
osteopontin (reviewed in[22]). In animal models, αvβ3
antagonists have been shown to reduce SMC migration,
SMC proliferation and neointima formation following
vascular injury[14,23].
In this study, insulin stimulated a proliferative response in
quiescent HASMC maintained in 0.5% FBS that was simi-
lar in magnitude to that observed with PDGF-BB. These
results are consistent with previous studies which showed
that insulin can stimulate proliferation of cultured SMC
and also enhance proliferative responses to other
mitogens[24-26]. Insulin has also been found to stimu-
late neointimal formation and proliferation of organ cul-
tures of saphenous veins and internal mammary
arteries[27]. Saphenous vein responses to insulin were
similar in magnitude to those observed with PDGF-BB
whereas insulin was a less efficacious mitogen than
PDGF-BB in internal mammary cultures. In contrast to
these studies, Obata et al.[28] found that low concentra-
tions of insulin stimulated insulin receptor substrate-1
phosphorylation and amino acid uptake but not thymi-
dine incorporation into DNA in rat aortic SMC. The con-
centrations of insulin used by Obata et al (1–10 nmol/L)
were approximately 100 fold lower than used in the
present studies.
We found that focal adhesions as delineated by anti-vin-
culin staining formed rapidly following treatment of qui-
escent HASMC with insulin and that αvβ3 antagonists
partially inhibited this response. Vinculin is one of the
first actin binding proteins recruited into focal adhe-
sions[29]. It is widely used as a marker of 'classic' focal
adhesions, which are usually located at the cell periphery,
are highly tyrosine phosphorylated, and contain αvβ3
integrins. Vinculin is also found in focal complexes,
which are short-lived structures that mature into focal
adhesions.
Recent studies have highlighted the existence of two
major signaling pathways that are initiated by insulin
binding to the insulin receptor and which mediate insulin
action[15,16]. One pathway, which involves IRS proteins
and phosphatidylinositol 3-kinase, appears to be respon-
sible for most, if not all, of the metabolic aspects of insu-
lin action. The second signaling pathway, involving Ras
and mitogen activated protein kinase (MAPK), is respon-
sible for proliferative responses to insulin. Doronzo et al
reported that insulin increased ERK 1/2 and JNK1 phos-
phorylation in HASMC in a time dependent manner
beginning within 5 minutes of treatment[19]. In the
present studies, we found that antagonism of αvβ3 inhib-
ited insulin-induced activation of JNK1, but not ERK 1/2,
in HASMC. JNK1 is a member of the mitogen activated
protein kinase superfamily that is activated by dual phos-
phorylation at a Thr-Pro-Tyr motif and once activated,
functions to phosphorylate c-jun at amino terminal serine
regulatory sites which increases activity of the transcrip-
tion factor AP-1. A clear link between JNK1 activation and
proliferation in insulin-treated HASMC has not been
established although JNK antagonists has been reportedPage 8 of 11
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Effect of c7E3, m7E3 and eptifibatide on insulin-induced focal adhesion formationFigure 5
Effect of c7E3, m7E3 and eptifibatide on insulin-induced focal adhesion formation. Growth arrested HASMC were 
treated with m7E3, c7E3 (both antibodies were used at 30 μg/ml) or eptifibatide (10 μmol/L) as indicated for one hour. Insulin 
(1 μmol/L) or vehicle were added and five minutes later, focal adhesions in 50 representative cells were determined using vin-
culin staining. Data represent the mean ± SEM from four independent experiments. [* – p = 0.05 relative to insulin].
A.
B.
Control Insulin 
Cardiovascular Diabetology 2008, 7:36 http://www.cardiab.com/content/7/1/36to inhibit proliferation of cultured SMC in other sys-
tems[30,31]. In studies utilizing the rat carotid balloon
injury model, transfection of a dominant negative JNK
prior to injury prevented neointimal formation and mark-
edly suppressed SMC proliferation in both the intima and
the media after rat carotid artery injury[32].
The inhibitory effect of αvβ3 antagonists on JNK1 activa-
tion occurs in response to a variety of stimuli. In addition
to inhibiting JNK1 activation in response to insulin, αvβ3
antagonists inhibit α-thrombin-induced[9] and TFB-
induced[33] JNK1 activation in SMC. Several potential
mechanisms that might explain these results are suggested
by recent studies. Activation of the small G protein Rho is
mediated by integrin engagement[34] and recently Ohtsu
et al reported that activation of Rho, and its effector Rho-
kinase/ROCK was required for angiotensin II-induced
JNK activation in SMC. Alternatively, studies in myo-
cytes[35] and HEK cells[21,36] have implicated the for-
mation of protein complexes involving focal adhesion
kinase in activation of JNK.
αvβ3 antagonists inhibited insulin-induced proliferation
without blocking ERK 1/2 phosphorylation. The bio-
chemical steps involved in signal transduction through
the ERK pathway are well established but less is known
about how these signals are implemented into specific
biological responses, and in particular the role of intracel-
lular localization of members of this pathway. Following
activation, ERK localizes to different subcellular compart-
ments, including focal adhesions, and phosphorylates
specific proteins leading to cellular responses. The specif-
icity of the biological response is likely to be at least par-
tially controlled by the localization of signaling, which
enables ERK activity to be directed towards specific tar-
gets. Integrin engagement is necessary for active ERK local-
ization to focal adhesions suggesting that a potential
mechanism whereby integrin antagonism could inhibit
growth but not ERK phosphorylation is via interrupting
ERK targeting[37].
Tirofiban had no effect on insulin-induced proliferation,
consistent with prior studies showing that tirofiban does
not antagonize αvβ3[5]. The different affinities of eptifi-
batide and tirofiban for αvβ3 are not surprising given that
eptifibatide is a synthetic, cyclic peptide with a Lys-Gly-
Asp (KGD) sequence whereas tirofiban is a nonpeptide
derivative of tyrosine. Tirofiban was used at a concentra-
tion of 30 μmol/L and eptifibatide was used at various
concentrations between 5 and 100 μmol/L in our studies.
This concentration of tirofiban is approximately 700 fold
greater than peak plasma concentration observed in
patients (40 ng/ml) receiving a continuous infusion[38].
There is wide inter-individual variation in plasma levels
however, and it is also unknown whether tirofiban con-
centrations are higher within the vessel wall than in
plasma.
Intimal thickening due to abnormal proliferation of vas-
cular smooth muscle cells is the major cause of revascular-
ization failures in diabetics. Since αvβ3 integrin expression
is upregulated in atherosclerotic lesions and at sites of bal-
loon angioplasty, these results suggest that one way to
potentially regulate insulin effects on SMC at sites of vas-
cular healing is via antagonism of αvβ3.
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